266 related articles for article (PubMed ID: 25825070)
1. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.
Gutierrez JA; Carrion AF; Avalos D; O'Brien C; Martin P; Bhamidimarri KR; Peyton A
Liver Transpl; 2015 Jun; 21(6):823-30. PubMed ID: 25825070
[TBL] [Abstract][Full Text] [Related]
2. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.
Pungpapong S; Aqel B; Leise M; Werner KT; Murphy JL; Henry TM; Ryland K; Chervenak AE; Watt KD; Vargas HE; Keaveny AP
Hepatology; 2015 Jun; 61(6):1880-6. PubMed ID: 25722203
[TBL] [Abstract][Full Text] [Related]
3. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S
Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562
[TBL] [Abstract][Full Text] [Related]
5. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
Pillai AA; Wedd J; Norvell JP; Parekh S; Cheng N; Young N; Spivey JR; Ford R
Am J Gastroenterol; 2016 Feb; 111(2):250-60. PubMed ID: 26832650
[TBL] [Abstract][Full Text] [Related]
6. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
Martini S; Sacco M; Strona S; Arese D; Tandoi F; Dell Olio D; Stradella D; Cocchis D; Mirabella S; Rizza G; Magistroni P; Moschini P; Ottobrelli A; Amoroso A; Rizzetto M; Salizzoni M; Saracco GM; Romagnoli R
Liver Int; 2017 Jan; 37(1):62-70. PubMed ID: 27344058
[TBL] [Abstract][Full Text] [Related]
7. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.
Punzalan CS; Barry C; Zacharias I; Rodrigues J; Mehta S; Bozorgzadeh A; Barnard GF
Clin Transplant; 2015 Dec; 29(12):1105-11. PubMed ID: 26358816
[TBL] [Abstract][Full Text] [Related]
9. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
Crittenden NE; Buchanan LA; Pinkston CM; Cave B; Barve A; Marsano L; McClain CJ; Jones CM; Marvin MR; Davis EG; Kuns-Adkins CB; Gedaly R; Brock G; Shah MB; Rosenau J; Cave MC
Liver Transpl; 2016 May; 22(5):635-43. PubMed ID: 26915588
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
Degré D; Sersté T; Lasser L; Delwaide J; Starkel P; Laleman W; Langlet P; Reynaert H; Bourgeois S; Vanwolleghem T; Negrin Dastis S; Gustot T; Geerts A; Van Steenkiste C; de Galocsy C; Lepida A; Orlent H; Moreno C
PLoS One; 2017; 12(1):e0170933. PubMed ID: 28125694
[TBL] [Abstract][Full Text] [Related]
11. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Lawitz E; Matusow G; DeJesus E; Yoshida EM; Felizarta F; Ghalib R; Godofsky E; Herring RW; Poleynard G; Sheikh A; Tobias H; Kugelmas M; Kalmeijer R; Peeters M; Lenz O; Fevery B; De La Rosa G; Scott J; Sinha R; Witek J
Hepatology; 2016 Aug; 64(2):360-9. PubMed ID: 26704148
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study.
O'Leary JG; Fontana RJ; Brown K; Burton JR; Firpi-Morell R; Muir A; O'Brien C; Rabinovitz M; Reddy R; Ryan R; Shprecher A; Villadiego S; Prabhakar A; Brown RS
Transpl Int; 2017 Feb; 30(2):196-208. PubMed ID: 27896858
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.
Sanchez Antolin G; Testillano M; Pascasio JM; Narvaez Rodriguez I; Prieto M; Otero A; Herrero JI; Londoño M; Fernandez Vazquez I; Castells L;
Transplant Proc; 2016 Nov; 48(9):3013-3016. PubMed ID: 27932134
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1.
Lutchman G; Nguyen NH; Chang CY; Ahmed A; Daugherty T; Garcia G; Kumari R; Gupta S; Doshi D; Nguyen MH
Aliment Pharmacol Ther; 2016 Oct; 44(7):738-46. PubMed ID: 27506182
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
Nair S; Satapathy SK; Gonzalez HC
Exp Clin Transplant; 2017 Jun; 15(3):314-319. PubMed ID: 26926117
[TBL] [Abstract][Full Text] [Related]
16. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
Aqel BA; Pungpapong S; Leise M; Werner KT; Chervenak AE; Watt KD; Murphy JL; Ryland K; Keaveny AP; McLemore R; Vargas HE
Hepatology; 2015 Oct; 62(4):1004-12. PubMed ID: 26096332
[TBL] [Abstract][Full Text] [Related]
17. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Castedal M; Segenmark M; Cederberg S; Skoglund C; Weiland O
Scand J Gastroenterol; 2017 May; 52(5):585-588. PubMed ID: 28270038
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
Sulkowski MS; Vargas HE; Di Bisceglie AM; Kuo A; Reddy KR; Lim JK; Morelli G; Darling JM; Feld JJ; Brown RS; Frazier LM; Stewart TG; Fried MW; Nelson DR; Jacobson IM;
Gastroenterology; 2016 Feb; 150(2):419-29. PubMed ID: 26497081
[TBL] [Abstract][Full Text] [Related]
19. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Pearlman BL; Ehleben C; Perrys M
Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience.
El-Khayat HR; Fouad YM; Maher M; El-Amin H; Muhammed H
Gut; 2017 Nov; 66(11):2008-2012. PubMed ID: 27511197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
